Over the past few decades, advances in hematology have illuminated how a delicate balance between stem cell self-renewal and ...

A new national study shows for the first time that people exposed to Agent Orange face a higher risk of developing ...

Without medical evidence that affirms a connection between Agent Orange and myelodysplastic syndrome, patients have struggled ...

Long-term follow-up of the IMEG trial reveals potential survival benefits of a metal stent in low-risk MDS patients, ...

Racial disparities are known to occur with many diseases, including numerous cancers, with Black individuals having lower survival rates than other racial/ethnic groups. However, there have not been ...

Azacitidine and decitabine belong to a class of antineoplastic agents known as DNA methyltransferase inhibitors (DMTIs). Each is paired with cedazuridine, a cytidine deaminase inhibitor, to help the ...

Peripheral blood sample MRD assessment will likely come into routine clinical use in the next few years, according to an expert who specializes in CLL. Researchers sought to determine whether adding ...

The combination of decitabine/cedazuridine and venetoclax achieved a 91% overall response rate in HR-MDS and CMML patients, with early responses observed. Median overall survival reached 30 months, ...

Social worker Marie Brewer talks about the challenges of supporting a loved one with myelodysplastic syndrome (MDS) and ways to find assistance and treatment options. Myelodysplastic syndromes (MDS) ...

Myelodysplastic syndrome (MDS) arises from defective blood stem cells that progressively lose their normal functions.